Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders
GeroScience · 2024
DOI: 10.1007/s11357-024-01120-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift GeroScience, 2024. Verfasst von Yazhou Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Translational Gerontology Branch, National Institute On Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Incretins, Glucagon-Like Peptide 1, Neurodegenerative Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Ministry of Science and Technology, Taiwan, Michael J. Fox Foundation for Parkinson's Research.
Abstract (Originalsprache)
The endogenous incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) possess neurotrophic, neuroprotective, and anti-neuroinflammatory actions. The dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin reduces degradation of endogenous GLP-1 and GIP, and, thereby, extends the circulation of these protective peptides. The current nonhuman primate (NHP) study evaluates whether human translational sitagliptin doses can elevate systemic and central nervous system (CNS) levels of GLP-1/GIP in naive, non-lesioned NHPs, in line with our prior rodent studies that demonstrated sitagliptin efficacy in preclinical models of Parkinson’s disease (PD). PD is an age-associated neurodegenerative disorder whose current treatment is inadequate. Repositioning of the well-tolerated and efficacious diabetes drug sitagliptin provides a rapid approach to add to the therapeutic armamentarium for PD. The pharmacokinetics and pharmacodynamics of 3 oral sitagliptin doses (5, 20, and 100 mg/kg), equivalent to the routine clinical dose, a tolerated higher clinical dose and a maximal dose in monkey, were evaluated. Peak plasma sitagliptin levels were aligned both with prior reports in humans administered equivalent doses and with those in rodents demonstrating reduction of PD associated neurodegeneration. Although CNS uptake of sitagliptin was low (cerebrospinal fluid (CSF)/plasma ratio 0.01), both plasma and CSF concentrations of GLP-1/GIP were elevated in line with efficacy in prior rodent PD studies. Additional cellular studies evaluating human SH-SY5Y and primary rat ventral mesencephalic cultures challenged with 6-hydroxydopamine, established cellular models of PD, demonstrated that joint treatment with GLP-1 + GIP mitigated cell death, particularly when combined with DPP-4 inhibition to maintain incretin levels. In conclusion, this study provides a supportive translational step towards the clinical evaluation of sitagliptin in PD and other neurodegenerative disorders for which aging, similarly, is the greatest risk factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Gerontology Branch, National Institute On Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
- Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan, 35053.
- Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
- Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
- Departments of Psychiatry and Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
- Cadre Bioscience, Saint Louis, MO, 63110, USA.
ORCID-Profile: Nigel H Greig
Förderung
- NIA NIH HHS
- Ministry of Science and Technology, Taiwan
- Michael J. Fox Foundation for Parkinson's Research
- National Health Research Institutes, Taiwan
- National Institute on Aging
Zitieren
APA
Li, Y., Vaughan, K. L., Wang, Y., Yu, S. J., Bae, E. K., Tamargo, I. A., Kopp, K. O., Tweedie, D., Chiang, C. C., Schmidt, K. T., Lahiri, D. K., Tones, M. A., Zaleska, M. M., Hoffer, B. J., Mattison, J. A., & Greig, N. H. (2024). Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders. GeroScience. https://doi.org/10.1007/s11357-024-01120-4
Vancouver
Li Y, Vaughan KL, Wang Y, Yu SJ, Bae EK, Tamargo IA, et al. Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders. GeroScience. 2024. doi:10.1007/s11357-024-01120-4
BibTeX
@article{Li2024,
author = {Li, Yazhou and Vaughan, Kelli L and Wang, Yun and Yu, Seong-Jin and Bae, Eun-Kyung and Tamargo, Ian A and Kopp, Katherine O and Tweedie, David and Chiang, Cheng-Chuan and Schmidt, Keith T and Lahiri, Debomoy K and Tones, Michael A and Zaleska, Margaret M and Hoffer, Barry J and Mattison, Julie A and Greig, Nigel H},
title = {Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders},
journal = {GeroScience},
year = {2024},
doi = {10.1007/s11357-024-01120-4}
}
EUVIMED